Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTB-010
- Development stage
- Unknown
- Lead developer
- NantBio
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**NTB-010** is a nanoparticle albumin-bound (nab) formulation of 17-AAG (17-allylamino-17-demethoxygeldanamycin), a geldanamycin analogue and potent inhibitor of heat shock protein 90 (HSP90). HSP90 is a molecular chaperone critical for the stability and function of oncogenic client proteins, making NTB-010 a targeted small-molecule therapy designed to disrupt cancer cell proliferation and survival. Developed initially by NantBioScience in collaboration with Celgene, it was planned for Phase I trials in hematological malignancies and solid tumors around 2014-2015 to improve the solubility and tolerability of 17-AAG, which had prior development challenges due to hepatotoxicity.[3][7][12]
02
Targets
HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on NTB-010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTB-010.